Clinical trial • Phase I • Oncology

ABBV-CLS-484 for Metastatic or locally advanced tumours | Advanced cancer

Phase I trial of ABBV-CLS-484 for Metastatic or locally advanced tumours | Advanced cancer. 98 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Metastatic or locally advanced tumours | Advanced cancer
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
29-12-2023
First CTIS Authorization Date
11-03-2024

Trial design

Phase I trial across 8 sites in France, Spain.

Target Sample Size
98

Recruitment

Planned Sample Size
98
Recruitment Window Months
62

Geography

Total Number Of Sites
8
Total Number Of Participants
200

France

Earliest CTIS Part Ii Submission Date
03-09-2023
Latest Decision Or Authorization Date
15-09-2025
Processing Time Days
743
Number Of Sites
5
Number Of Participants
100

Sites

Site Name
Hospital Foch
Contact Person Name
Jaafar Bennouna
Contact Person Email
j.bennouna@hopital-foch.com
Site Name
Institut De Cancerologie De L Ouest
Department Name
Medical oncology
Contact Person Name
Judith Raimbourg
Site Name
Institut Universitaire Du Cancer Toulouse-Oncopole
Contact Person Name
Iphigenie Korakis
Site Name
Centre Antoine Lacassagne
Contact Person Name
Esma Saada-Bouzid
Site Name
Institut Paoli-Calmettes
Contact Person Name
Cecile Vicier
Contact Person Email
vicierc@ipc.unicancer.fr

Spain

Earliest CTIS Part Ii Submission Date
03-09-2023
Latest Decision Or Authorization Date
29-09-2025
Processing Time Days
757
Number Of Sites
3
Number Of Participants
100

Sites

Site Name
Hospital Universitario Hm Sanchinarro
Contact Person Name
Emiliano Calvo Aller
Contact Person Email
emiliano.calvo@startmadrid.com
Site Name
Institut Catala D'oncologia
Department Name
Unidad de Fase 1
Contact Person Name
Marta Gil Martin
Contact Person Email
mgilmartin@iconcologia.net
Site Name
Hospital Universitario 12 De Octubre
Contact Person Name
Jon Zugazagoitia Fraile
Contact Person Email
j.zugazagoitia.imas12@h12o.es

Sponsor

Primary sponsor

Full Name
Calico Life Sciences LLC
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
ABBV-CLS-484
Combination Treatment
Yes

Related trials

Other published trials that may interest you.